Evidence map›Paper›PMID 34266883›Full record

ArticleJournal for immunotherapy of cancer2021

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer.

Matthew D Galsky, Arjun V Balar, Peter C Black, Matthew T Campbell, Gail S Dykstra, Petros Grivas, Shilpa Gupta, Christoper J Hoimes, Lidia P Lopez, Joshua J Meeks and 5 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05700344 (Multicentric, Observational Study to Evaluate Real World Data of Avelumab in First Line Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma, a SOGUG Study), which is not on this map. Cited by 25 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 6 pooled it
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05700344 completednot on this mapstarted 2022, after this paper: background citation

Multicentric, Observational Study to Evaluate Real World Data of Avelumab in First Line Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma, a SOGUG Study

TypeobservationalSponsorSpanish Oncology Genito-Urinary GroupRan2022 to 2023Enrolled125ConditionsMetastatic Urothelial CarcinomaArmsAvelumab
3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 6 syntheses or guidelines pooled it, 30 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Guideline
  4. Gender bias in shared decision-making among cancer care guidelines: A systematic review.Health expectations : an international journal of public participation in health care and health policy · 2023
    Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Article
  12. Article
  13. Real-world data on avelumab in first-line maintenance therapy for advanced or metastatic urothelial carcinoma: the SOGUG-AVELUMAB RWD study.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Observational
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 13 institutions in 2 countries.

Matthew D GalskyTisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Arjun V BalarPerlmutter Cancer Center, New York University Langone Medical Center, New York, New York, USA.
Peter C BlackDepartment of Urologic Sciences, The University of British Columbia, Vancouver, British Columbia, Canada.
Matthew T CampbellDepartment of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Gail S DykstraBladder Cancer Advocacy Network (BCAN), Bethesda, Maryland, USA.
Petros GrivasDepartment of Medicine, Division of Oncology, University of Washington, Seattle, Washington, USA.
Shilpa GuptaDepartment of Hematology and Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, USA.
Christoper J HoimesDepartment of Medicine, Duke Cancer Institute, Duke University, Durham, North Carolina, USA.
Lidia P LopezDivision of Hematology-Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, California, USA.
Joshua J MeeksNorthwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Elizabeth R PlimackDepartment of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA.
Jonathan E RosenbergDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Neal ShoreCarolina Urologic Research Center, Myrtle Beach, South Carolina, USA.
Gary D SteinbergDepartment of Urology and Perlmutter Cancer Center, NYU Langone Medical Center, New York, New York, USA.
Ashish M KamatDepartment of Urology under Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA akamat@mdanderson.org.
NYU Langone Health · USThe University of Texas MD Anderson Cancer Center · USBladder Cancer Advocacy Network · USCancer Research Center · USCarolina Urologic Research Center · USCleveland Clinic · USDuke University · USFox Chase Cancer Center · USIcahn School of Medicine at Mount Sinai · USMemorial Sloan Kettering Cancer Center · USNorthwestern University · USUniversity of British Columbia · CAUniversity of California, Los Angeles · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A number of immunotherapies have been developed and adopted for the treatment of urothelial cancer (encompassing cancers arising from the bladder, urethra, or renal pelvis). For these immunotherapies to positively impact patient outcomes, optimal selection of agents and treatment scheduling, especially in conjunction with existing treatment paradigms, is paramount. Immunotherapies also warrant specific and unique considerations regarding patient management, emphasizing both the prompt identification and treatment of potential toxicities. In order to address these issues, the Society for Immunotherapy of Cancer (SITC) convened a panel of experts in the field of immunotherapy for urothelial cancer. The expert panel developed this clinical practice guideline (CPG) to inform healthcare professionals on important aspects of immunotherapeutic treatment for urothelial cancer, including diagnostic testing, treatment planning, immune-related adverse events (irAEs), and patient quality of life (QOL) considerations. The evidence- and consensus-based recommendations in this CPG are intended to give guidance to cancer care providers treating patients with urothelial cancer.

Indexed as

Guidelines as TopicHumansImmunotherapySocieties, MedicalUrinary Bladder Neoplasmsantineoplastic protocolsguidelines as topicimmunotherapyurinary bladder neoplasmsurologic neoplasms

Identifiers

PMID34266883
PMCPMC8286774
OpenAlexW3181256475

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.